APA (7th ed.) Citation

V, D., HH, M., D, R., RF, R., O, G., P, F., . . . S, J. (2025). Performance evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Comparison with cobas® EBV for epstein-barr virus DNA quantification in immunocompromised patients, a multicenter study. Diagnostic microbiology and infectious disease, 113(3), 116956. https://doi.org/10.1016/j.diagmicrobio.2025.116956

Chicago Style (17th ed.) Citation

V, Doseeva, Mostafa HH, Rhoads D, Relich RF, Garner O, Findeisen P, Eigner U, English A, and Johnson S. "Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Comparison with Cobas® EBV for Epstein-barr Virus DNA Quantification in Immunocompromised Patients, a Multicenter Study." Diagnostic Microbiology and Infectious Disease 113, no. 3 (2025): 116956. https://doi.org/10.1016/j.diagmicrobio.2025.116956.

MLA (9th ed.) Citation

V, Doseeva, et al. "Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Comparison with Cobas® EBV for Epstein-barr Virus DNA Quantification in Immunocompromised Patients, a Multicenter Study." Diagnostic Microbiology and Infectious Disease, vol. 113, no. 3, 2025, p. 116956, https://doi.org/10.1016/j.diagmicrobio.2025.116956.